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Abstract
Purpose—Adolescents and young adults (AYAs) with cancer have not experienced
improvements in survival to the same extent as children and older adults. We compared outcomes
among children (<15 years), AYAs (15-40 years) and older adults (>40 years) receiving allogeneic
hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML).
Patients and Methods—Our cohort consisted of 900 children, 2708 AYA and 2728 older adult
recipients of HLA-identical sibling or unrelated donor (URD) transplant using myeloablative or
reduced-intensity/non-myeloablative conditioning. Outcomes were assessed over three time
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periods (1980-1988, 1989-1997, 1998-2005) for sibling and two time periods (1989-1997,
1998-2005) for URD HCT. Analyses were stratified by donor type.
Results—Overall survival for AYAs using either siblings or URD improved over time. Although
children had better and older adults had worse survival compared to AYAs, improvements in
survival for AYAs did not lag behind those for children and older adults. After sibling donor HCT,
five-year adjusted survival for the three time periods was 40%, 48% and 53% for children, 35%,
41% and 42% for AYAs and 22%, 30% and 34% for older adults. Among URD HCT recipients,
five-year adjusted survival for the two time periods was 38% and 37% for children, 24% and 28%
for AYAs and 19% and 23% for older adults. Improvements in survival occurred due to a
reduction in risk of treatment-related mortality. The risk of relapse did not change over time.
Conclusion—Improvements in survival among AYAs undergoing allogeneic HCT for AML
have paralleled those among children and older adults.
Introduction
Cancer is the leading cause of non-accidental death among adolescents and young adults
(AYA) in the United States (U.S.).1,2 Tremendous improvements in cancer treatments have
taken place over the last several decades; however, survival for AYAs with cancer has not
improved to the same extent as for children and older adults with cancer.1-4 The reasons for
these outcome disparities among AYA cancer patients are not well understood.3,5
Contributing factors may include age-related differences in biology, socioeconomic status,
access to care, adherence to medical plans, participation rates in clinical trials, treatment in
centers experienced with the care of AYA patients, caregiver availability, and other
psychosocial issues.6
Innovations in transplantation care since the 1980s have led to incremental improvements in
survival and reduction of treatment-related mortality (TRM) among hematopoietic cell
transplantation (HCT) recipients.7,8 Whether improvements in transplant outcomes have
occurred to the same degree across all age groups, particularly AYAs, is not well known.
Using data from the Center for International Blood and Marrow Transplant Research
(CIBMTR), we compared outcomes of children, AYAs and older adult recipients of
allogeneic HCT for acute myeloid leukemia (AML) to determine whether AYAs have
experienced improvements in survival at rates that are similar to their younger and older
counterparts.
Methods
Data source and patients
The CIBMTR is a research affiliation of the International Bone Marrow Transplant Registry
(IBMTR) and the National Marrow Donor Program (NMDP) established in 2004, which
comprises a voluntary working group of more than 450 transplantation centers worldwide
that contribute detailed data on consecutive allogeneic and autologous hematopoietic cell
transplants to a Statistical Center at the Medical College of Wisconsin in Milwaukee and the
NMDP Coordinating Center in Minneapolis. Participating centers are required to report all
transplants consecutively; compliance is monitored by on-site audits. Patients are followed
longitudinally, with yearly follow-up. Computerized checks for discrepancies, physicians’
review of submitted data and on-site audits of participating centers ensure data quality.
Observational studies conducted by the CIBMTR are performed in compliance with the
Privacy Rule (HIPAA) as a Public Health Authority, and in compliance with all applicable
federal regulations pertaining to the protection of human research participants as determined
by continuous review of the Institutional Review Board (IRB) of the National Marrow
Donor Program and the Medical College of Wisconsin since 1985.
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For this study, we included patients who had received their first allogeneic HCT for AML
using either an HLA-identical sibling donor (matched sibling donor, MSD) or unrelated
donor (URD), from 1980 to 2005 at a U.S. transplant center. Patients transplanted using
myeloablative, reduced-intensity (RIC) or non-myeloablative (NMA) conditioning regimens
were included in this analysis. Patients with acute promyelocytic leukemia, recipients of
cord blood grafts and recipients of prior autologous HCT were excluded. Patients were
divided into three groups based on age at transplantation: children (<15 years), AYA (15-40
years),2 and older adults (>40 years).
All surviving recipients included in this analysis were contacted retrospectively and
provided informed consent for participation in the NMDP research program. Informed
consent was waived by the NMDP IRB for all deceased recipients. Approximately 10% of
surviving patients would not provide consent for use of research data. To adjust for the
potential bias introduced by exclusion of non-consenting surviving patients, a corrective
action modeling process randomly excluded the same percentage of deceased patients using
a biased coin randomization with exclusion probabilities based on characteristics associated
with not providing consent for use of the data in survivors.9
Outcomes and study definitions
The primary objective of this study was to compare change over time in rates of overall
survival (OS), leukemia-free survival (LFS), relapse and TRM among children, AYAs and
older adults. For OS, death from any cause was considered an event. LFS was defined as
survival in complete remission (CR) after HCT. Relapse was defined as leukemia
recurrence. TRM was defined as death in CR. All outcomes were assessed from the date of
transplantation.
Disease status was classified as early, intermediate or advanced.10 Early disease included
AML in CR1. AML in ≥ CR2 was categorized as intermediate and patients in relapse/
primary induction failure were classified as advanced disease. The NMDP classification of
HLA-matching status was used for URD recipients (well-matched, partially-matched or
mismatched).11 Conditioning regimens were classified as myeloablative or RIC/NMA based
on CIBMTR definitions.12 Where information was available, cytogenetic risk was classified
according to standard criteria as good, intermediate or poor.13,14
Statistical methods
Summaries of patient-, disease- and treatment-related characteristics were produced for the
three age groups. Univariate probabilities of OS and LFS were calculated using the Kaplan-
Meier estimator.15 Probabilities of relapse and TRM were estimated using a cumulative
incidence function method.16
Separate analyses were performed for MSD and URD recipients. To evaluate changes in
outcomes over time, we divided the MSD cohort into three time periods (1980-1988,
1989-1997 and 1998-2005) based on year of transplantation. Because the NMDP began
facilitating URD HCT in the U.S. in 1986, the URD cohort was evaluated over two time
periods (1989-1997 and 1998-2005).
Cox proportional hazards models were used to adjust for significant covariates while
comparing the three age groups. All factors were examined for proportional hazards using a
time-dependent covariate approach. The non-proportional hazards were addressed by
introducing a time-dependent covariate to appropriately model early versus later events in
OS (<3 months and ≥ 3 months), relapse (<3 months and ≥ 3 months), and TRM (<6 months
and ≥ 6 months) in multivariable analyses for MSD recipients. A backward regression
model selection technique was used to identify significant covariates to be included in the
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models. The main effects tested in all multivariate analysis models for the outcomes of
interest were age and time period of transplantation. Interaction between age and time period
was also examined. All p-values were two-sided, and risk factors of P<0.05 were included in
the final model. In addition to age and time period of transplant, the covariates considered in
the multivariable models included: gender, Karnofsky/Lansky performance status at HCT
(<90 vs. ≥ 90), disease status at HCT (CR1 vs. CR2 vs. other), time from diagnosis to HCT
(<6 vs. 6-12 vs. >12 months), graft source (peripheral blood vs. bone marrow), donor-
recipient gender mismatch, and donor-recipient cytomegalovirus (CMV) status. HLA
matching status was also considered for URD recipients. Transplant practices such as use
conditioning regimen intensity and graft-versus-host disease prophylaxis regimens changed
at different rates over time among the three age-groups; hence, we did not adjust for these
variables in multivariate analyses.




Table 1 describes patient, disease and transplant characteristics. Overall, 900 children, 2708
AYA and 2728 older adults met the study inclusion criteria. The numbers of patients
receiving a transplant increased over time for all age groups. This increase was largely due
to greater utilization of URD transplants. Among URD recipients, a greater proportion
received HLA well-matched grafts in the most recent time period. Other notable trends over
time included increasing utilization of peripheral blood as a graft source (particularly among
AYA and older adult recipients) and larger numbers of older adults undergoing RIC/NMA
HCT.
Outcomes after HLA-identical sibling donor HCT
Univariate analysis showed that the probability of OS at five-years post transplant improved
significantly for patients transplanted from 1998-2005, compared to 1980-1988, for all age
groups (Table 2, Figure 1A). Also, survival was inversely correlated with age for all three
time periods; five-year OS for children, AYAs and older adults receiving transplants for
AML in 1998-2005 were 64%, 43% and 31%, respectively. Change in five-year OS for
AYAs paralleled that for children and older adults for the time periods studied (Table 2). In
multivariate analyses of the MSD cohort, older age at HCT was associated with increased
risk of overall mortality. Transplantation in a more recent time period, in general, was
associated with a lower risk of mortality (Table 3). We also examined survival over time
within each age group using multivariate analyses (Table 4); the AYA and older adult age
groups improved the most in OS over time, especially in the early post-transplant period for
1998-2005.
A similar trend was observed for LFS. Five-year LFS rates improved over time for all age
groups; better LFS was seen for children than AYAs, who in turn had better LFS than older
adults (Table 2). Again, change in LFS for AYA’s paralleled that of children and older
adults. Multivariate analysis showed that older adults had significantly worse LFS rates,
while AYAs had comparable LFS rates to those of children (Table 3). The time period of
transplantation was not found to be significantly associated with LFS, which was confirmed
in multivariate analysis by age group (Table 4).
Cumulative incidence of TRM decreased over time, especially among AYAs and older
adults, and was again inversely related to patient age at time of transplantation (Table 2).
Multivariate analysis showed there was a strong age correlation with relative risk of TRM,
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with AYAs having twice the risk and older adults having more than three times the risk of
dying from transplant-related complications than children (Table 3). Patients had a lower
relative risk of TRM in the 1989-1997 and 1998-2005 time periods than in the 1980-1988
timeframe. This was further confirmed in analyses for each age group (Table 4); TRM
improved from 1980-1988 to 1989-1997 for all three age groups. Early TRM (<6 months
post-transplant) improved significantly from 1989-1997 to 1998-2005 for AYAs and older
adults.
Multivariate analysis of all MSD showed differences in relapse risks by age and time period
(Table 3). In analyses within each age group, while there were no statistically significant
changes in relapse rates for children and AYA patients over the three time periods
considered, early relapse rates (<3 months after transplantation) increased among older
patients (Table 4). The relative risk of early relapse among older patients transplanted from
1998-2005 was 1.6 times higher than those transplanted from 1989-1997 (hazard ratio [HR]
1.59, 95% CI 1.17-2.16, P=0.003) and 3 times higher than those transplanted from
1980-1988 (HR 3.01, 95% CI 1.37-6.60, P=0.006).
We found no significant interactions between age group and time period for any of the
endpoints studied. We observed no notable trends in outcome disparities between the 15-25
and 26-40 year age groups (Appendix Table 1). Although limited by small numbers,
unadjusted analyses for a subset of patients who had received myeloablative HCT for AML
in CR1 did not show a negative trend in survival for AYAs (Appendix Table 2).
Appendix table 3 shows hazard ratios for factors other than time period of transplantation
and age-group that were significantly associated with outcomes following MSD HCT.
Outcomes after unrelated donor HCT
Similar to recipients of MSD transplants, survival for URD HCT recipients also improved
significantly over time (1989-1997 vs. 1998-2005), and was inversely related to age at
transplant (Table 2, Figure 1B). Similar to sibling donor HCT, changes in five-year OS for
AYAs paralleled those of children and older adults (Table 2). In multivariate analyses, older
age at time of HCT was associated with increasing risk of overall mortality (Table 5). For
the URD cohort, we also observed a significant association between time period of
transplant and OS after URD HCT, with mortality risk improving for patients transplanted in
the most recent time period. Furthermore, analysis by age group showed significant
improvement in OS for AYAs and older adults, but not for children, from 1998-2005 when
compared to 1989-1997 (Table 4).
Results similar to those for OS were observed for LFS, with improved LFS for patients
transplanted from 1998-2005 compared to 1989-1997 (Table 2). In multivariate analyses
that included all URD HCT patients, children and those with more recent transplants
(1998-2005) experienced better LFS (Table 5). Analyses restricted by age group showed that
LFS had significantly improved in the most recent time period for AYAs and older adults
but not for children (Table 4).
Cumulative incidence of TRM significantly decreased over time for all age groups (Table
2). Multivariate analyses showed that older age and transplant in an earlier time period were
associated with higher risks of TRM (Table 5). Improvements in TRM over time were seen
in AYAs and older adults but not in children (Table 4).
Cumulative incidence of relapse did not change over the two time periods for children and
AYAs, but increased for older adults (Table 2). This was also observed on multivariate
analyses by age group, where older adults had a significantly higher risk of relapse if
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transplanted in 1998-2005 compared to 1989-1997 (HR 1.70, 95% CI 1.01-2.87, P=0.05)
(Table 4).
As with the analysis of MSD HCT recipients, we found no significant interactions between
age group and time period for any of the endpoints studied. Exploratory analyses showed
that the 15-25 year age group had superior OS compared to the 26-40 year age group in both
time periods studied (Appendix Table 1). Again, unadjusted analyses in a small subset of
patients who had received myeloablative HCT for AML in CR1 did not show a negative
trend in survival for AYAs (Appendix Table 2).
Appendix table 4 shows hazard ratios for factors other than time period of transplantation
and age-group that were significantly associated with outcomes following URD HCT.
Discussion
Our study shows that survival for AYAs after allogeneic HCT for AML using either MSD or
URD has improved over time, and unlike survival rates of cancer in general, improvements
in survival for AYAs after transplant have not necessarily lagged behind those for children
and older adults. Children have the best survival, followed by AYAs, and older adults have
the worst survival rates after allogeneic HCT for AML.
Several factors have been implicated in the lack of progress against cancer in AYAs.1-4
These include under-recognition of cancer risk and adverse cancer outcomes in this
population, and restricted or delayed access to care given that AYAs have the highest
uninsured rate of any age group in the country. AYAs have an exceedingly low participation
rates in cancer clinical trials, which has resulted in a poor understanding of the patient and
tumor biology that distinguishes cancers in this age group.1-3 Although AYAs with cancer,
in general, have not seen the same improvement in survival compared to their younger and
older counterparts,1-4 our study did not find age-related disparities in outcomes
improvement in recent years. Children, who already had better outcomes than AYAs and
older patients in the earliest years of the study, maintained but did not improve their
outcomes over time, whereas both AYAs and older adults are doing better in recent years
but still not achieving the success seen in children.
Surveillance Epidemiology and End Results (SEER) data show similar survival trends
among patients with AML.17 Five-year survival rates for AML decline with advancing age.
In analyses that evaluated five-year survival rates for AML by age according to era (four
equal six-year intervals from 1975 to 1998), survival remained inversely correlated with age
and improvements in survival in all age categories occurred over time. However, during the
late 1980s and 1990s, improvement in AML survival in those less than 30 years of age was
negligible and considerably less than in older patients. We observed a similar plateau in
outcomes in children undergoing HCT for AML.
Similar to another CIBMTR analysis,7 improvement in survival for all age groups has
largely been driven by decreasing risks of TRM after both MSD and URD HCT. Rates of
relapse did not improve over time and in fact worsened among older adults. This likely
reflects changes in transplantation practices over time. Improvements in understanding of
AML prognostic factors and HCT techniques and supportive care have allowed earlier
transplantation in high-risk patients more recently. Although data on cytogenetic risk was
missing for a large proportion of patients transplanted in the earlier time periods, more
patients received transplantation in 1998-2005 for higher risk disease. Also, older patients
are inherently at higher risk for AML relapse and the number of older patients transplanted
in the most recent time period increased substantially because of the availability of RIC/
NMA regimens. Relapse continues to be a major reason for treatment failure after allogeneic
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HCT for AML, and more research and advancement in this area is still needed to optimize
survival after allogeneic HCT for all age groups.18
Our study has the usual limitations of a retrospective cohort study using registry-level data.
Our findings are specific to allogeneic HCT and AML and may not be generalizable to other
malignancies prevalent among AYAs that are treated with HCT. Also, there may be a
selection bias at the level of centers in offering transplantation as therapy to patients who
were more likely to have favorable outcomes. For instance, patients with inadequate
caregiver support and financial resources and those who were non-compliant with therapy
may not have been referred for or offered allogeneic HCT as a treatment option for their
leukemia. AYAs are more likely to encounter access barriers than other age groups.1,2 Our
study did not address issues related to access to allogeneic HCT for AYAs.
Although we found no disparities in survival improvement over time, other issues remain in
determining what causes the disparity in outcomes between AYAs and the other age groups.
These include the availability of AYA-appropriate patient educational materials and
resources, appropriate methods of patient communication, and AYA-specific post-transplant
quality of life and transition to survivorship. AYAs who develop chronic GVHD face a
chronic health condition that can be associated with significant long-term morbidity and
quality of life impairment, and they may need age-specific treatments and supportive care.
In conclusion, our study shows that improvements in survival among AYAs undergoing
allogeneic HCT for AML parallel those of other age groups.
Appendix Tables
Appendix Table 1
Unadjusted probability of overall survival and leukemia-free survival, and cumulative
incidences of relapse and treatment-related mortality at five years after transplantation for
patients aged 15-25 years and 26-40 years
Age 15-25 years Age 26-40 years
Outcome N Probability(95% CI) N
Probability
(95% CI) P-value
Matched sibling donor HCT
Overall survival
 1980-1988 176 42 (35-50)% 286 34 (29-40)% 0.08
 1989-1997 194 46 (38-53)% 410 37 (32-42)% 0.06
 1998-2005 77 47 (34-61)% 144 41 (32-49)% 0.41
Leukemia-free survival
 1980-1988 173 40 (33-48)% 281 32 (27-38)% 0.09
 1989-1997 193 43 (35-50)% 402 33 (29-38)% 0.04
 1998-2005 76 46 (33-60)% 140 39 (31-48)% 0.39
Relapse
 1980-1988 173 33 (26-40)% 281 43 (37-49)% 0.03
 1989-1997 193 34 (27-41)% 402 34 (29-39)% 0.94
 1998-2005 76 40 (27-53)% 140 37 (29-46)% 0.75
Treatment related mortality
 1980-1988 173 27 (21-34)% 281 25 (20-30)% 0.61
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Age 15-25 years Age 26-40 years
Outcome N Probability(95% CI) N
Probability
(95% CI) P-value
 1989-1997 193 24 (18-30)% 402 33 (28-38)% 0.02
 1998-2005 76 14 (6-23)% 140 23 (16-31)% 0.09
Unrelated donor HCT
Overall survival
 1989-1997 189 22 (16-28)% 316 13 (10-17)% 0.02
 1998-2005 381 33 (28-38)% 535 26 (22-30)% 0.04
Leukemia-free survival
 1989-1997 186 21 (15-27)% 314 13 (9-17)% 0.02
 1998-2005 377 30 (25-35)% 522 25 (21-29)% 0.13
Relapse
 1989-1997 186 29 (23-36)% 314 28 (24-33)% 0.88
 1998-2005 377 34 (29-39)% 522 34 (30-38)% 0.92
Treatment related mortality
 1989-1997 186 50 (43-57)% 314 59 (54-64)% 0.05
 1998-2005 377 36 (31-41)% 522 41 (37-46)% 0.12
Appendix Table 2
Unadjusted outcomes at five years after transplantation in the subset of children, AYAs and
older adults with AML in CR1 who received a myeloablative HCT
Outcome 1980-1988* 1989-1997* 1998-2005* P-value
N N N
Matched sibling donor HCT
Overall survival
 Children 68 60 (48-72)% 120 58 (49-67)% 56 69 (55-81)% 0.41
 Adolescent and young adults 262 49 (43-55)% 299 57 (52-63)% 96 52 (42-63)% 0.16
 Older adults 23 35 (17-55)% 152 35 (28-43)% 146 47 (38-56)% 0.13
Leukemia-free survival
 Children 67 61 (49-72)% 119 54 (44-63)% 55 65 (51-78)% 0.33
 Adolescent and young adults 256 46 (40-52)% 297 53 (47-58)% 95 51 (41-61)% 0.32
 Older adults 22 32 (14-52)% 150 35 (28-43)% 144 46 (37-55)% 0.16
Relapse
 Children 67 15 (7-24)% 119 38 (30-47)% 55 21 (11-33)% <0.01
 Adolescent and young adults 256 17 (13-22)% 297 20 (16-25)% 95 28 (20-38)% 0.09
 Older adults 22 14 (3-31)% 150 22 (16-29)% 144 25 (18-32)% 0.40
Treatment related mortality
 Children 67 24 (15-35)% 119 8 (4-14)% 55 14 (6-26)% 0.02
 Adolescent and young adults 256 37 (31-43)% 297 27 (22-32)% 95 20 (13-29)% <0.01
 Older adults 22 55 (34-74)% 150 43 (35-51)% 144 29 (22-37)% 0.02
Unrelated donor HCT
Majhail et al. Page 8













Outcome 1980-1988* 1989-1997* 1998-2005* P-value
N N N
Overall survival
 Children - 44 36 (23-51)% 91 34 (24-45)% 0.81
 Adolescent and young adults - 93 22 (15-31)% 235 41 (34-48)% <0.01
 Older adults - 45 22 (11-35)% 261 34 (28-41)% 0.09
Leukemia-free survival
 Children - 44 32 (19-46)% 91 35 (25-45)% 0.71
 Adolescent and young adults - 92 22 (14-31)% 231 40 (33-46)% <0.01
 Older adults - 45 22 (11-35)% 257 34 (28-41)% 0.09
Relapse
 Children - 44 30 (17-44)% 91 35 (25-45)% 0.53
 Adolescent and young adults - 92 12 (6-19)% 231 24 (19-30)% <0.01
 Older adults - 45 16 (7-27)% 257 27 (21-33)% 0.07
Treatment related mortality
 Children - 44 39 (25-53)% 91 30 (21-40)% 0.33
 Adolescent and young adults - 92 66 (56-76)% 231 36 (30-43)% <0.01
 Older adults - 45 62 (48-76)% 257 39 (33-45)% <0.01
*
Probability and 95% confidence intervals
Appendix Table 3
Factors other than year of transplant and age group that were significantly associated with
overall survival, leukemia-free survival, relapse and treatment-related mortality among
recipients of HLA-identical sibling donor transplantation
Variable Hazard ratio* 95% confidenceintervals P-value
Overall survival
Cytogenetic risk
 Good 1.0 . <0.01
 Intermediate 1.28 1.02-1.60 0.04
 Poor 1.79 1.39-2.31 <0.01
 Unknown 1.48 1.17-1.87 <0.01
Disease status at transplant
 First complete remission 1.0 . <0.01
 Second complete remission 1.49 1.24-1.78 <0.01
 Other 2.14 1.90-2.40 <0.01
 Unknown 4.56 2.26-9.23 <0.01
Time from diagnosis to transplant
 < 6 months 1.00 . <0.01
 6-12 months 1.24 1.09-1.40 <0.01
 > 12 months 0.95 0.81-1.10 0.46
 Unknown 0.52 0.07-3.75 0.52
KPS score at transplant
 < 90 1.0 . <0.01
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Variable Hazard ratio* 95% confidenceintervals P-value
 ≥ 90 0.74 0.66-0.82 <0.01
 Unknown 0.74 0.55-0.99 0.05
Gender
 Male 1.0 . <0.01
 Female 0.87 0.79-0.96
Leukemia-free survival
Cytogenetic risk
 Good 1.0 . <0.01
 Intermediate 1.31 1.05-1.64 0.02
 Poor 1.89 1.47-2.43 <0.01
 Unknown 1.46 1.15-1.84 <0.01
Disease status at transplant
 First complete remission 1.0 . <0.01
 Second complete remission 1.58 1.32-1.88 <0.01
 Other 2.20 1.96-2.47 <0.01
 Unknown 4.03 1.90-8.53 <0.01
Time from diagnosis to transplant
 < 6 months 1.0 . .<0.01
 6-12 months 1.23 1.08-1.39 <0.01
 > 12 months 0.90 0.78-1.05 0.18
 Unknown 0.40 0.06-2.90 0.37
KPS score at transplant
 < 90 1.0 . <0.01
 ≥ 90 0.76 0.69-0.84 <0.01
 Unknown 0.82 0.61-1.10 0.18
Gender
 Male 1.0 . <0.01
 Female 0.86 0.78-0.95
Relapse
Cytogenetic risk
 Good 1.0 . <0.01
 Intermediate 1.78 1.25-2.53 <0.01
 Poor 2.86 1.96-4.16 <0.01
 Unknown 1.70 1.17-2.45 <0.01
Disease status at transplant
 First complete remission 1.00 . <0.01
 Second complete remission 2.23 1.72-2.86 <0.01
 Other 3.40 2.89-3.99 <0.01
 Unknown 4.28 1.36-13.45 0.01
Time from diagnosis to transplant
 < 6 months 1.00 . <0.01
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Variable Hazard ratio* 95% confidenceintervals P-value
 6-12 months 1.17 0.99-1.39 0.07
 > 12 months 0.58 0.47-0.72 <0.01
KPS score at transplant
 < 90 1.00 . <0.01
 ≥ 90 0.73 0.63-0.84 <0.01
 Unknown 0.90 0.61-1.33 0.59
Treatment-related mortality
Disease status at transplant
 First complete remission 1.0 . <0.01
 Second complete remission 1.14 0.89-1.45 0.31
 Other 1.41 1.19-1.67 <0.01
 Unknown 4.01 1.48-10.84 <0.01
Time from diagnosis to transplant
 < 6 months 1.0 . <0.01
 6-12 months 1.29 1.08-1.54 <0.01
 > 12 months 1.35 1.09-1.66 <0.01
 Unknown 2.75 0.38-19.98 0.32
KPS score at transplant
 < 90 1.0 . <0.01
 ≥ 90 0.79 0.68-0.92 <0.01
 Unknown 0.77 0.49-1.20 0.25
*
Hazard ratios refer to hazards of death or relapse
Appendix Table 4
Factors other than year of transplant and age group that were significantly associated with
overall survival, leukemia-free survival, relapse and treatment-related mortality among
recipients of unrelated donor transplantation
Variable Hazard ratio* 95% confidenceintervals P-value
Overall survival
Cytogenetic risk
 Good 1.0 . <0.01
 Intermediate 1.17 0.97-1.41 0.10
 Poor 1.48 1.21-1.80 <0.01
 Unknown 1.35 1.11-1.63 <0.01
Disease status at transplant
 First complete remission 1.0 . <0.01
 Second complete remission 1.18 1.04-1.35 0.01
 Other 1.82 1.65-2.01 <0.01
 Unknown 1.65 0.86-3.17 0.13
Time from diagnosis to transplant
 < 6 months 1.0 . <0.01
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Variable Hazard ratio* 95% confidenceintervals P-value
 6-12 months 1.12 1.02-1.24 0.02
 > 12 months 0.87 0.77-0.97 0.01
 Unknown 0.63 0.27-1.51 0.30
KPS score at transplant
 < 90 1.0 . <0.01
 ≥ 90 0.74 0.68-0.80 <0.01
 Unknown 0.69 0.59-0.81 <0.01
Ethnicity/Race
 White 1.0 . <0.01
 Black 1.50 1.25-1.80 <0.01
 Asian/Pacific-Islander 1.06 0.78-1.43 0.73
 Hispanic 1.04 0.87-1.25 0.66
 Other 1.01 0.63-1.63 0.97
Leukemia-free survival
Cytogenetic risk
 Good 1.0 . <0.01
 Intermediate 1.19 0.99-1.42 0.07
 Poor 1.50 1.23-1.82 <0.01
 Unknown 1.34 1.11-1.62 <0.01
Disease status at transplant
 First complete remission 1.0 . <0.01
 Second complete remission 1.22 1.07-1.39 <0.01
 Other 1.99 1.80-2.19 <0.01
 Unknown 1.45 0.74-2.89 0.28
Time from diagnosis to transplant
 < 6 months 1.0 . <0.01
 6-12 months 1.11 1.01-1.22 0.03
 > 12 months 0.83 0.74-0.92 <0.01
 Unknown 0.66 0.27-1.62 0.36
KPS score at transplant
 < 90 1.0 . <0.01
 ≥ 90 0.74 0.68-0.80 <0.01
 Unknown 0.74 0.63-0.86 <0.01
Relapse
Cytogenetic risk
 Good 1.0 . <0.01
 Intermediate 1.58 1.15-2.16 <0.01
 Poor 2.04 1.47-2.84 <0.01
 Unknown 1.73 1.25-2.39 <0.01
Disease status at transplant
 First complete remission 1.0 . <0.01
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Variable Hazard ratio* 95% confidenceintervals P-value
 Second complete remission 1.39 1.13-1.70 <0.01
 Other 3.17 2.74-3.66 <0.01
 Unknown 1.55 0.59-4.08 0.40
Time from diagnosis to transplant
 < 6 months 1.0 . <0.01
 6-12 months 1.08 0.95-1.23 0.26
 > 12 months 0.59 0.50-0.69 <0.01
 Unknown 1.01 0.32-3.18 0.98
KPS score at transplant
 < 90 1.0 . <0.01
 ≥ 90 0.68 0.60-0.76 <0.01
 Unknown 0.86 0.71-1.05 0.13
Treatment-related mortality
Disease status at transplant
 First complete remission 1.0 . <0.01
 Second complete remission 1.07 0.93-1.24 0.34
 Other 1.32 1.16-1.50 <0.01
 Unknown 0.91 0.43-1.93 0.80
KPS score at transplant
 < 90 1.0 . <0.01
 ≥ 90 0.79 0.71-0.89 <0.01
 Unknown 0.58 0.45-0.74 <0.01
Ethnicity/Race
 White 1.0 . <0.01
 Black 1.68 1.33-2.13 <0.01
 Asian/Pacific-Islander 1.22 0.82-1,81 0.33
 Hispanic 1.13 0.89-1.43 0.31
 Other 0.99 0.45-2.00 0.99
*
Hazard ratios refer to hazards of death or relapse
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Trends over time for five-year adjusted overall survival after HLA-identical sibling donor
(A) and unrelated donor (B) hematopoietic cell transplantation for AML. The edges of the
box plots represent 95% confidence intervals.
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Table 2
Unadjusted probability of overall survival and leukemia-free survival, and cumulative incidence of relapse and
treatment-related mortality at five years after transplantation
Outcome 1980-1988* 1989-1997* 1998-2005* P-value
†
Matched sibling donor HCT
Overall survival 0.23
 Children 45 (41-50)% 53 (49-57)% 64 (57-71)%
 Adolescent and young adults 37 (35-39)% 40 (38-42)% 43 (40-46)%
 Older adults 21 (19-23)% 26 (25-27)% 31 (30-33)%
Leukemia-free survival 0.76
 Children 45 (36-55)% 47 (39-55)% 58 (47-69)%
 Adolescent and young adults 35 (31-40)% 36 (32-40)% 42 (35-49)%
 Older adults 20 (10-31)% 26 (22-30)% 29 (25-34)%
Relapse <0.01
 Children 32 (24-42)% 43 (35-50)% 26 (17-37)%
 Adolescent and young adults 26 (22-30)% 34 (30-38)% 38 (31-45)%
 Older adults 13 (5-23)% 31 (26-35)% 40 (36-44)%
Treatment related mortality 0.01
 Children 22 (15-31)% 10 (6-15)% 16 (8-25)%
 Adolescent and young adults 39 (35-44)% 30 (26-34)% 20 (15-26)%
 Older adults 67 (55-79)% 44 (39-48)% 31 (27-35)%
Unrelated donor HCT
Overall survival 0.87
 Children - 28 (26-30)% 38 (36-40)%
 Adolescent and young adults - 17 (16-17)% 29 (28-30)%
 Older adults - 15 (14-16)% 26 (25-27)%
Leukemia-free survival 0.77
 Children - 25 (19-31)% 34 (29-40)%
 Adolescent and young adults - 16 (13-19)% 27 (24-30)%
 Older adults - 15 (11-19)% 24 (21-26)%
Relapse 0.03
 Children - 42 (36-49)% 40 (35-46)%
 Adolescent and young adults - 29 (25-33)% 34 (31-37)%
 Older adults - 25 (20-30)% 39 (37-42)%
Treatment related mortality 0.05
 Children - 33 (27-39 )% 26 (21-31)%
 Adolescent and young adults - 56 (51-60)% 39 (36-43)%
 Older adults - 60 (54-66)% 37 (34-40)%
*
Probability and 95% confidence intervals
†
P-value for comparison in improvement in 5-year outcomes between the three age groups (2 degrees of freedom)
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Table 3
Results of multivariate analyses for overall survival, leukemia-free survival, relapse and treatment-related






Age at transplant, years
 Children 1.0 - <0.01
‡
 Adolescent and young adults 1.22 1.03-1.44 0.02
 Older adults 1.68 1.41-2.00 <0.01
Year of transplant
 1980-1988 1.0 - <0.01
§
 1989-1997 0.83 0.73-0.95 <0.01
 1998-2005 (> 3 months after HCT) 0.55 0.44-0.70 <0.01
 1998-2005 (≥ 3 months after HCT) 0.88 0.74-1.05 0.15
Leukemia-free survival
∥
Age at transplant, years
 Children 1.0 - <0.01
‡
 Adolescent and young adults 1.14 0.97-1.34 0.11
 Older adults 1.47 1.24-1.75 <0.01
Year of transplant
 1980-1988 1.0 - 0.06
‡
 1989-1997 0.87 0.77-1.00 0.05
 1998-2005 0.83 0.70-0.99 0.02
Relapse
¶
Age at transplant, years
 Children 1.0 - 0.02
‡
 Adolescent and young adults 0.76 0.62-0.93 <0.01
 Older adults 0.77 0.62-0.96 0.02
Year of transplant
 1980-1988 1.0 - <0.01
§
 1989-1997 1.10 0.90-1.34 0.35
 1998-2005 (> 3 months after HCT) 1.66 1.24-2.22 <0.01
 1998-2005 (≥ 3 months after HCT) 1.18 0.92-1.52 0.20
Treatment-related mortality**
Age at transplant, years
 Children 1.0 - <0.01
‡
 Adolescent and young adults 2.06 1.55-2.73 <0.01
 Older adults 3.40 2.53-4.56 <0.01
Year of transplant

















 1980-1988 1.0 - <0.01
§
 1989-1997 0.65 0.55-0.77 <0.01
 1998-2005 (> 6 months after HCT) 0.38 0.30-0.48 <0.01
 1998-2005 (≥ 6 months after HCT) 0.64 0.47-0.85 <0.01
*
Hazard ratios refer to hazards of death or relapse
†
Other variables significantly associated with overall survival included cytogenetic risk at diagnosis, disease status at transplant, time from
diagnosis to transplant, performance status score at transplant and patient gender (also see Appendix Table 3)
‡
Overall P-value, 2 degrees of freedom test
§
Overall P-value, 3 degrees of freedom test
∥
Other variables significantly associated with leukemia-free survival included gender, cytogenetic risk at diagnosis, disease status at transplant,
time from diagnosis to transplant and performance status score at transplant (also see Appendix Table 3)
¶
Other variables significantly associated with relapse included cytogenetic risk at diagnosis, disease status at transplant, time from diagnosis to
transplant and performance status score at transplant (also see Appendix Table 3)
**
Other variables significantly associated with treatment-related mortality included disease status at transplant, time from diagnosis to transplant
and performance status score at transplant (also see Appendix Table 3)
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Table 5
Results of multivariate analyses for overall survival, leukemia-free survival, relapse and treatment-related






Age at transplant, years
 Children 1.0 - <0.01
‡
 Adolescent and young adults 1.33 1.18-1.50 <0.01
 Older adults 1.43 1.26-1.62 <0.01
Year of transplant
 1989-1997 1.0 - <0.01
 1998-2005 0.74 0.67-0.81
Leukemia-free survival
§
Age at transplant, years
 Children 1.0 - <0.01
‡
 Adolescent and young adults 1.22 1.08-1.38 <0.01
 Older adults 1.28 1.14-1.45 <0.01
Year of transplant
 1989-1997 1.0 - <0.01
 1998-2005 0.80 0.73-0.87
Relapse
∥
Age at transplant, years
 Children 1.0 - 0.03
‡
 Adolescent and young adults 0.80 0.68-0.95 0.01
 Older adults 0.90 0.76-1.05 0.18
Year of transplant
 1989-1997 1.0 - 0.10
 1998-2005 1.13 0.98-1.30
Treatment-related mortality
¶
Age at transplant, years
 Children 1.0 - <0.01
‡
 Adolescent and young adults 1.83 1.53-2.18 <0.01
 Older adults 1.90 1.58-2.29 <0.01
Year of transplant
 1989-1997 1.0 - <0.01
 1998-2005 0.57 0.51-0.64
*
Hazard ratios refer to hazards of death or relapse
†
Other variables significantly associated with overall survival included race/ethnicity, cytogenetic risk at diagnosis, disease status at transplant,
time from diagnosis to transplant and performance status score at transplant (also see Appendix Table 4)
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‡
Overall P-value, 2 degrees of freedom test
§
Other variables significantly associated with leukemia-free survival included cytogenetic risk at diagnosis, disease status at transplant, time from
diagnosis to transplant and performance status score at transplant (also see Appendix Table 4)
∥
Other variables significantly associated with relapse included cytogenetic risk at diagnosis, disease status at transplant, time from diagnosis to
transplant and performance status score at transplant (also see Appendix Table 4)
¶
Other variables significantly associated with treatment-related mortality included race/ethnicity, disease status at transplant and performance
status score at transplant (also see Appendix Table 4)
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